COMMUNIQUÉS West-GlobeNewswire

HCW Biologics Delivers a Major Update for its T-Cell Engager Program Revealing Mechanism of Action and Validating Tissue Factor as Target for Treatment of Solid Tumors
27/04/2026
Its lead T-Cell Engager HCW11-018b is shown to penetrate into the tumor microenvironment with potent and antigen-specific anti-pancreatic cancer activities IND application expected to be filed in first half of 2027 to [...]
Sagimet Biosciences Provides Strategic and Corporate Updates
27/04/2026
Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. planned to initiate in second half of 2026 First-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567 ongoing Further MASH [...]
Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy
27/04/2026
– Alignment reached on chemistry, manufacturing, and control (CMC) elements of ATH434 Phase 3 development program – – Positive feedback supports readiness for Phase 3 initiation with manufacturing scale-up progressing [...]
Seer Board of Directors Unanimously Rejects Revised Unsolicited Proposal from Radoff-JEC Group
27/04/2026
Board Determines Proposal Significantly Undervalues Seer and Is Not in the Best Interests of Stockholders REDWOOD CITY, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER) (“Seer” or the “Company”), the [...]
Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer
27/04/2026
Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel demonstrated a highly statistically significant improvement versus paclitaxel alone in the key secondary endpoint of median progression-free [...]
KFSH Highlights Scalable AI Integration Model at C3 Davos of Healthcare™ Silicon Valley Summit
27/04/2026
SUNNYVALE, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- As global health systems shift from isolated digital initiatives to integrated, data-driven care models, King Faisal Specialist Hospital & Research Centre (KFSH [...]
Real-World Data on EXPAREL® Shows Reduced Opioid Use and Lower Total Medical Costs in Medicare Patients Undergoing Total Hip Arthroplasty
27/04/2026
-- Findings show significant reductions in opioid consumption, healthcare resource utilization, and total medical costs -- BRISBANE, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), [...]
Evaxion promotes Birgitte Rønø to joint role of Chief Scientific and Chief Operating Officer
27/04/2026
Management remit expansion reflecting organization alignment to maximize external engagement and strategy execution COPENHAGEN, Denmark, April 27, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio [...]
Secura Bio Announces Journal of Clinical Oncology Publication of Final Results of Duvelisib PRIMO Phase 2 Trial in Relapsed/Refractory Peripheral T-cell Lymphoma
27/04/2026
Single agent duvelisib demonstrated clinically meaningful response rates, including a substantial proportion of complete responses, in a heavily pretreated PTCL population Responses highest in angioimmunoblastic T-cell [...]
Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities
27/04/2026
$225 million funded at closing, with an additional $225 million warrant tranche Financing funds operations through anticipated Phase 3 MASH 52-week data readout Financing was led by Deep Track Capital, with [...]
NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer
27/04/2026
VANCOUVER, British Columbia, April 27, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative [...]
Weight Watchers Announces Actions to Utilize Up to $40 million to Pay Down Debt
27/04/2026
NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight Watchers” or the “Company”), the global leader in science-backed weight management, today announced that it intends to utilize up [...]
Solésence, Inc. Announces Appointment of New Independent Director
27/04/2026
Marc James to Join Board of Directors and Serve on Audit, Compensation, and Nominating Committees ROMEOVILLE, Ill., April 27, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven [...]
Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill
27/04/2026
Builds Support for Accelerated Access to SkinJect® for Gorlin Syndrome patients with a Rare Autosomal Dominant Disease PHILADELPHIA, April 27, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or [...]
BriaCell Announces Six Clinical Data Presentations at ASCO 2026
27/04/2026
Final randomized Phase 2 Bria-IMT™ survival and quality of life data to be presented Biomarker analyses from the ongoing Phase 3 study evaluating predictors of response PHILADELPHIA and VANCOUVER, British Columbia, [...]
Clearmind Medicine Announces Evaluation of its Psychedelic-Based Treatment (MEAI) for Potential FDA Breakthrough Therapy Designation
27/04/2026
Positive clinical results from Alcohol Use Disorder clinical trial may strengthen potential for eligibility for Breakthrough Therapy Designation Vancouver, Canada, April 27, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine [...]
CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients
27/04/2026
– The study primary endpoint was met, showing non-inferiority vs. standard antimicrobial regimen in fungal free survival at Day 90 – – Study showed favorable benefit for toxicity related discontinuations and drug-drug [...]
BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026
27/04/2026
CARSON CITY, Nev., April 27, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases [...]
Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis
27/04/2026
Topline data is on track for anticipated readout in the summer of 2026 WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission [...]

Pages